Quarterly intravenous eptinezumab prevents migraine

PHILADELPHIA – Results from a pair of dose-ranging, randomized studies showed one IV eptinezumab dose cut migraine recurrences for 3 months.

Conference Coverage

Nearly 20% of migraineurs use opioids for migraine

PHILADELPHIA – People with 4 or more migraine headache days per month are more likely to use opioids, compared with people with fewer migraine...

Conference Coverage

Which migraineurs seek care from a neurologist?

PHILADELPHIA – A large number of patients with migraine who first seek care for migraine in a primary care setting receive an initial migraine...

Conference Coverage

Can mindfulness-based cognitive therapy treat migraine?

PHILADELPHIA – Mindfulness-based cognitive therapy for migraine may reduce migraine-related disability, even as the number of headache days and...

Conference Coverage

How does gender bias affect the headache field?

– Many female headache specialists report having experienced sexual harassment in the workplace, and...